



Call for Abstracts

2019 Annual Conference on Vaccinology Research (ACVR)

April 3-5, 2019

Baltimore, MD

The National Foundation for Infectious Diseases (NFID) invites abstract submissions of original research in the areas of: behavioral science and vaccine hesitancy; epidemiology and burden of vaccine-preventable diseases; new and emerging vaccines; novel methods in disease detection and diagnosis; vaccine policy, programs, and practice; vaccine production, testing, and delivery technologies; and vaccine safety and monitoring. Abstracts are peer-reviewed for quality of research, educational and scientific content, and overall impact. Accepted abstracts are scheduled as either poster or oral presentations based on quality and anticipated interest.

How to Submit:

All abstracts must be submitted electronically through the ACVR online submission site (<http://bit.ly/2019ACVRabstracts>). All users will be required to create an account. Users may begin the submission process and return to saved proposals at any time up until the submission deadline. Abstracts submitted by email, fax, or mail will not be accepted. Incomplete abstracts will not be reviewed.

Schedule:

November 2018	Call for Abstracts submission site opens
January 23, 2019	Abstract submission deadline - extended (11:59 PM ET)
February 2019	Notifications issued for all submitted abstracts
February 18, 2019	Presenter registration deadline
April 3-5, 2019	2019 Annual Conference on Vaccinology Research Hyatt Regency Baltimore Inner Harbor Baltimore, MD

Topics for Abstract Submission:

The submitting author must select the most appropriate topic from the list below. The ACVR Planning Committee reserves the right to change the topic of accepted abstracts.

- Behavioral Science and Vaccine Hesitancy
- Epidemiology and Burden of Vaccine-Preventable Diseases
- New and Emerging Vaccines
- Novel Methods in Disease Detection and Diagnosis
- Vaccine Policy, Programs, and Practice
- Vaccine Production, Testing, and Delivery Technologies
- Vaccine Safety and Monitoring

Abstract Format:

All abstracts must be submitted in English and must reflect original work. Abstracts based on prior presentations with updated information and additional data generated and/or analyzed are permitted. Multiple submissions of the same abstract will automatically be rejected.

Abstracts must contain the following components:

- **Abstract Title:** (75 word limit) a concise title that summarizes the content
- **Background:** (150 word limit) a concise statement of the issue under investigation or a hypothesis
- **Methods:** (200 word limit) the experimental methods used (including the statistical analyses employed)
- **Results & Conclusions:** (250 word limit) a summary of specific findings and results (statistical analyses used to support the conclusions should be included; concluding statements such as “the results will be discussed” or “to be completed” are not acceptable)
- **References:** Users are **required** to submit at least one literature reference/citation to support research/data (multiple references are strongly recommended.). Use the conventional style for listing references as referred by the American Medical Association (AMA) Manual of Style: A Guide for Authors and Editors. Sample references are available at: <https://jamanetwork.com/journals/jama/pages/instructions-for-authors#SecReferences>.
- **Author(s):** (limit of 10 authors) Submittals must include the First Author, Presenting Author (individual who will be presenting the research at the conference if accepted), and any Co-Authors of the work. Note that the full contact information will be requested for all authors. The system allows users to send an email to each of the authors for them to complete this information directly.
- **Learning Objective(s):** Users are **required** to submit at least one learning objective. Sample learning objectives are available at: www.nfid.org/professional-education/presenter-resources.

Note:

It is the responsibility of the submitter to ensure that all submitted abstracts are correct. Any errors in spelling, grammar, or scientific fact in the abstract text may be reproduced as typed by the submitter.

Selection:

All abstract submissions will be reviewed by members of the ACVR Planning Committee for scientific merit and relevance to the field of vaccinology. Abstract submissions are reviewed for the following: a clearly stated hypothesis or issue; experimental and statistical methods used; specific findings (statements such as “the data will be presented” are unacceptable); and specific conclusions (statements such as “the results will be discussed” are unacceptable). Authors of accepted abstracts will be invited to present their work in a 10-minute oral presentation or as a poster presentation.

Poster and Oral Presenter Information:

Detailed information for preparing oral or poster presentations will be provided upon abstract acceptance. Oral presentations will be allotted a maximum of 10 minutes followed by 5 minutes for questions from the audience. Poster presentations will be displayed on standard poster boards, measuring 4 feet high by 8 feet wide (1.22 meters high by 2.44 meters wide), so the poster should be no wider than 6 feet (1.83 meters wide).

Registration & Attendance:

All abstract presenters must register for the conference and pay the appropriate registration fee no later than **February 18, 2019** or their abstract may be withdrawn from the program. Presenters who fail to appear at the conference at the specified time(s) will forfeit their registration fee and future abstract submissions may be automatically disqualified from consideration. The conference organizer does not provide any support for travel costs or registration fees.

Abstract Publication:

All abstracts will be published in the onsite program book. Select presentations may be included in future publications with author permission.

Awards:

[Maurice R. Hilleman Early-Stage Career Investigator Award](http://www.nfid.org/awards/hilleman-award) (www.nfid.org/awards/hilleman-award)

The Maurice R. Hilleman Early-Stage Career Investigator Award recognizes individuals in the early stages of their careers in any field of vaccinology. The awardee will receive \$10,000 to support their research, will be recognized during the NFID Luncheon at the 2019 ACVR, and will present a 10-minute summary of their research. In addition, the awardee will receive a travel stipend and complimentary registration for the 2020 Annual Conference on Vaccinology Research.

To apply for award consideration, applicants must:

1. At the time of submission, be currently enrolled, have recently completed training (e.g., internship, residency, fellowship, postdoctoral training, or similar educational program), or be within four years of having earned an advanced degree (masters or doctoral).
2. Submit an abstract under the “poster only” submission type. Finalists will present a poster at the 2019 ACVR. Following judging onsite, the winner will be announced and will present a 10-minute summary of their research during the conference.
3. Acknowledge that the award is funded in part by Merck & Co., Inc. Awardees must be in a position to accept funding from Merck. Furthermore, the Sunshine Act requires that Merck report any direct/indirect funding to US licensed physicians. Awardees of the Maurice R. Hilleman Early-Stage Career Investigator Award will be included in mandatory reporting to Centers for Medicare & Medicaid Services (CMS). All publications under the award must explicitly state that the awardees’ work has been performed as a Maurice R. Hilleman Early-Stage Career Investigator Award recipient. Acknowledgement must also be given to NFID and Merck as the sponsors supporting the award.